You are here
Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study.
Tuesday,2012-11-06 12:26 America/Los_Angeles — eenright
| Title | Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Kaplan, RC, Bůzková, P, Cappola, AR, Strickler, HD, McGinn, AP, Mercer, LD, Arnold, AM, Pollak, MN, Newman, AB |
| Journal | J Clin Endocrinol Metab |
| Volume | 97 |
| Issue | 6 |
| Pagination | 1970-6 |
| Date Published | 2012 Jun |
| ISSN | 1945-7197 |
| Keywords | African Continental Ancestry Group, Aged, Aged, 80 and over, Cardiovascular Diseases, European Continental Ancestry Group, Female, Follow-Up Studies, Humans, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Longitudinal Studies, Male, Mortality, Predictive Value of Tests, Risk Factors |
| Abstract | <p><b>BACKGROUND: </b>The association between changes in IGF-I and IGF binding protein (IGFBP) levels and mortality in older adults is unknown.</p><p><b>STUDY DESIGN: </b>Participants were 997 persons 77 to 100 yr old enrolled in the Cardiovascular Health Study All Stars Study. Plasma levels of IGF-I, IGFBP-1, and IGFBP-3 were assessed at two study examinations (1996-1997 and 2005-2006). Mortality was assessed between 2006 and 2010.</p><p><b>RESULTS: </b>Cumulative mortality (CM) was similar among individuals who had at least 10% decreases over time in IGF-I levels (CM = 29.6%), individuals who had at least 10% increases over time in IGF-I levels (CM = 24.7%), and individuals who had IGF-I levels remaining within ±10% over time (CM = 23.5%). Adjusted for age, sex, race, diabetes, body mass index, creatinine, albumin, and C-reactive protein, decreasing IGF-I level had no significant association with overall cancer mortality or noncancer mortality. Levels of IGFBP-1 increased markedly over time by 38% (median). Individuals with the largest increases in IGFBP-1 level over time had significantly increased risk of mortality. The adjusted hazard ratio per sd of IGFBP-1 change was 1.40 for overall cancer mortality (95% confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95% confidence interval = 1.02, 1.27; P = 0.02). Changes in IGFBP-3 levels were not significantly associated with mortality.</p><p><b>CONCLUSION: </b>Among older adults, decreasing IGF-I level over time does not predict subsequent all-cause mortality, whereas increasing IGFBP-1 predicts increased risk of mortality.</p> |
| DOI | 10.1210/jc.2011-2967 |
| Alternate Journal | J. Clin. Endocrinol. Metab. |
| PubMed ID | 22442270 |
| PubMed Central ID | PMC3387428 |
| Grant List | P30 AG024827 / AG / NIA NIH HHS / United States R01 HL075366 / HL / NHLBI NIH HHS / United States N01-HC-85085 / HC / NHLBI NIH HHS / United States R01 AG015928 / AG / NIA NIH HHS / United States U01 HL080295 / HL / NHLBI NIH HHS / United States N01-HC-85081 / HC / NHLBI NIH HHS / United States 1R01AG031890 / AG / NIA NIH HHS / United States N01 HC015103 / HC / NHLBI NIH HHS / United States R56 AG020098 / AG / NIA NIH HHS / United States P30-AG-024827 / AG / NIA NIH HHS / United States HL-075366 / HL / NHLBI NIH HHS / United States AG-20098 / AG / NIA NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States R01 HL094555 / HL / NHLBI NIH HHS / United States N01-HC-85086 / HC / NHLBI NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States HL094555 / HL / NHLBI NIH HHS / United States AG-027058 / AG / NIA NIH HHS / United States 2R01AG023629-05A2 / AG / NIA NIH HHS / United States N01-HC-85082 / HC / NHLBI NIH HHS / United States AG-023269 / AG / NIA NIH HHS / United States N01 HC-55222 / HC / NHLBI NIH HHS / United States N01-HC-85083 / HC / NHLBI NIH HHS / United States N01-HC-75150 / HC / NHLBI NIH HHS / United States N01-HC-85080 / HC / NHLBI NIH HHS / United States R01 HL080295 / HL / NHLBI NIH HHS / United States R01 AG020098 / AG / NIA NIH HHS / United States N01HC75150 / HL / NHLBI NIH HHS / United States N01-HC-85079 / HC / NHLBI NIH HHS / United States HL080295 / HL / NHLBI NIH HHS / United States N01-HC-85239 / HC / NHLBI NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States R01 AG027058 / AG / NIA NIH HHS / United States N01 HC045133 / HC / NHLBI NIH HHS / United States R01 AG031890 / AG / NIA NIH HHS / United States N01 HC035129 / HC / NHLBI NIH HHS / United States N01-HC-85084 / HC / NHLBI NIH HHS / United States |